Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMGMXQC)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
l-Stepholidine; 16562-13-3; (-)-Stepholidine; stepholidine; (S)-3,9-Dimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[3,2-a]isoquinoline-2,10-diol; S-Stepholidine; UNII-0UPX3E69W8; 0UPX3E69W8; Q-100198; (13aS)-3,9-dimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline-2,10-diol; 3,9-Dimethoxy-13a-alpha-berbine-2,10-diol; l-2,10-Dihydroxy-3,9-dimethyloxytetrahydropseudoberberine; L-(S)-Stepholidine; l-SPD; AC1OCEV4; 13a-alpha-BERBINE-2,10-DIOL, 3,9-DIMETHOXY-; GTPL8370; DIB014; CHEMBL487387; SCHEMBL10001966
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
|||||||||||||||||||||
|
|||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Osteosarcoma
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Kidney
Normal (Immortalized)
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
